{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05879367",
            "orgStudyIdInfo": {
                "id": "OT-21-101"
            },
            "organization": {
                "fullName": "Orbus Therapeutics, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma",
            "officialTitle": "An Open-label, Phase 1b Study to Evaluate the Safety and Tolerability of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma",
            "therapeuticArea": [
                "Other"
            ],
            "study": "evaluation-of-eflornithine-plus-temozolomide-in-patients-with-newly-diagnosed-glioblastoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-07-24",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12-15",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12-15",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-05-03",
            "studyFirstSubmitQcDate": "2023-05-19",
            "studyFirstPostDateStruct": {
                "date": "2023-05-30",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-16",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Orbus Therapeutics, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.",
            "detailedDescription": "This open label dose escalation and expansion study will be conducted using a standard dose-escalation design with escalating doses of eflornithine plus temozolomide at the approved dose level, followed by an expansion cohort that will further evaluate safety and preliminary efficacy of the combination at the recommended phase 2 dose.\n\nDuration of participation will be up to 56 weeks in total per patient:\n\nScreening Period - A maximum screening duration of 4 weeks.\n\nTreatment Period - Up to 48 weeks.\n\nFollow-Up Visit - 4 weeks from last treatment.\n\nA total of up to 66 patients will be enrolled in a non-randomized fashion (patients may be added to any of the dose levels below the RP2D to a maximum of approximately 20 per dose level with the intent of further characterizing safety and pharmacokinetics)."
        },
        "conditionsModule": {
            "conditions": [
                "Glioblastoma, IDH-wildtype",
                "Glioblastoma",
                "Glioblastoma Multiforme",
                "Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype",
                "GBM"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 66,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Eflornithine Dose Level 1 + Temozolomide",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Eflornithine (Dose Level 1)",
                        "Drug: Temozolomide"
                    ]
                },
                {
                    "label": "Eflornithine Dose Level 2 + Temozolomide",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Eflornithine (Dose Level 2)",
                        "Drug: Temozolomide"
                    ]
                },
                {
                    "label": "Eflornithine Dose Level -1 + Temozolomide",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Eflornithine (Dose Level -1)",
                        "Drug: Temozolomide"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Eflornithine (Dose Level 1)",
                    "description": "Eflornithine 2.3 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule",
                    "armGroupLabels": [
                        "Eflornithine Dose Level 1 + Temozolomide"
                    ],
                    "otherNames": [
                        "DFMO"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Eflornithine (Dose Level 2)",
                    "description": "Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule",
                    "armGroupLabels": [
                        "Eflornithine Dose Level 2 + Temozolomide"
                    ],
                    "otherNames": [
                        "DFMO"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Eflornithine (Dose Level -1)",
                    "description": "Eflornithine 1.75 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule",
                    "armGroupLabels": [
                        "Eflornithine Dose Level -1 + Temozolomide"
                    ],
                    "otherNames": [
                        "DFMO"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Temozolomide",
                    "description": "Temozolomide 150 mg/m2 (with option to escalate per USPI maintenance phase instructions) administered orally once daily on a 5 days on, 23 days off schedule",
                    "armGroupLabels": [
                        "Eflornithine Dose Level -1 + Temozolomide",
                        "Eflornithine Dose Level 1 + Temozolomide",
                        "Eflornithine Dose Level 2 + Temozolomide"
                    ],
                    "otherNames": [
                        "Temodar",
                        "TMZ"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Assessment of Dose Limiting Toxicities",
                    "description": "Protocol Defined Dose Limiting Toxicities",
                    "timeFrame": "8 weeks"
                },
                {
                    "measure": "Incidence of TEAEs All Grades",
                    "description": "All Grades",
                    "timeFrame": "52 weeks"
                },
                {
                    "measure": "Incidence of TEAEs Grade 3+",
                    "description": "Grade 3+",
                    "timeFrame": "52 weeks"
                },
                {
                    "measure": "Incidence of TEAEs Serious",
                    "description": "Serious",
                    "timeFrame": "52 weeks"
                },
                {
                    "measure": "Incidence of TEAEs Leading to Discontinuation",
                    "description": "Leading to Discontinuation",
                    "timeFrame": "48 weeks"
                },
                {
                    "measure": "Vital Signs (Heart and Respiratory Rate)",
                    "description": "Change from Baseline in Heart Rate and Respiratory Rate",
                    "timeFrame": "52 weeks"
                },
                {
                    "measure": "Vital Signs (Blood Pressure)",
                    "description": "Change from Baseline in Systolic Blood Pressure and Diastolic Blood Pressure",
                    "timeFrame": "52 weeks"
                },
                {
                    "measure": "Incidence of Treatment-Emergent Abnormalities in Clinical Laboratory Tests",
                    "description": "Lab abnormalities by CTCAE v5.0 Grade",
                    "timeFrame": "52 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Progression Free Survival",
                    "description": "Per RANO Criteria as assessed by MRI",
                    "timeFrame": "52 weeks"
                },
                {
                    "measure": "Overall Response Rate",
                    "description": "Per RANO Criteria as assessed by MRI",
                    "timeFrame": "52 weeks"
                },
                {
                    "measure": "Pharmacokinetics Cmax",
                    "description": "observed maximum concentration",
                    "timeFrame": "Baseline to Steady State (2 weeks)"
                },
                {
                    "measure": "Pharmacokinetics Cmin",
                    "description": "observed minimum concentration",
                    "timeFrame": "Baseline to Steady State (2 weeks)"
                },
                {
                    "measure": "Pharmacokinetics Tmax",
                    "description": "time of observed maximum concentration",
                    "timeFrame": "Baseline to Steady State (2 weeks)"
                },
                {
                    "measure": "Pharmacokinetics AUCt",
                    "description": "area under the concentration-time curve",
                    "timeFrame": "Baseline to Steady State (2 weeks)"
                },
                {
                    "measure": "Pharmacokinetics lambdaz",
                    "description": "elimination rate constant",
                    "timeFrame": "Baseline to Steady State (2 weeks)"
                },
                {
                    "measure": "Pharmacokinetics t 1/2",
                    "description": "elimination half life",
                    "timeFrame": "Baseline to Steady State (2 weeks)"
                },
                {
                    "measure": "QTcF-Concentration Relationship",
                    "description": "Assessment of change in QTcF relative to plasma concentration of eflornithine",
                    "timeFrame": "Baseline to Steady State (2 weeks)"
                },
                {
                    "measure": "Assessment of QTcF",
                    "description": "Change from baseline in QTcF",
                    "timeFrame": "Baseline to Steady State (2 weeks)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of World Health Organization (WHO) G4 classified GBM, IDH-wildtype per WHO 2021 tumor classification.\n* Completed external beam radiation therapy per standard of care.\n* Must have received at least 80% of planned daily doses of TMZ during chemoradiation.\n* Adequate hematologic, renal, hepatic, and other organ function as indicated by hematology and serum chemistry testing.\n* Willing to abstain from intercourse or use acceptable contraceptive methods.\n* If taking corticosteroids, must be on a stable or decreasing dose.\n\nExclusion Criteria:\n\n* Recent history of recurrent or metastatic cancer that could confound response assessments\n* Prior systemic chemotherapy for GBM other than temozolomide during external beam radiation therapy.\n* Prior Optune treatment.\n* Active infection or serious intercurrent medical illness.\n* Poorly controlled seizures.\n* Significant cardiac disease within 6 months of enrollment.\n* Poorly controlled diabetes.\n* Use of another investigational agent within 30 days of enrollment.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Monika Varga",
                    "role": "CONTACT",
                    "phone": "6506569424",
                    "email": "monika.varga@orbustherapeutics.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Howard Colman, MD, PhD",
                    "affiliation": "Huntsman Cancer Institute/ University of Utah",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Alabama at Birmingham",
                    "status": "RECRUITING",
                    "city": "Birmingham",
                    "state": "Alabama",
                    "zip": "35294",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Thiru Pillay",
                            "role": "CONTACT",
                            "phone": "205-934-1432",
                            "email": "Tpillay@uabmc.edu"
                        },
                        {
                            "name": "Louis B Nabors, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.52066,
                        "lon": -86.80249
                    }
                },
                {
                    "facility": "Henry Ford Hospital",
                    "status": "RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48202",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Meghan Gauronskas",
                            "role": "CONTACT",
                            "phone": "313-725-7871",
                            "email": "mgauron1@hfhs.org"
                        },
                        {
                            "name": "Angela Dunn",
                            "role": "CONTACT",
                            "phone": "313-725-7870",
                            "email": "adunn6@hfhs.org"
                        },
                        {
                            "name": "Tobias Walbert, MD, PhD, MPH",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "Columbia University Medical Center - Herbert Irving Pavilion",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10032",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Maria Diaz, MD",
                            "role": "CONTACT",
                            "phone": "212-342-0571",
                            "email": "md4157@cumc.columbia.edu"
                        },
                        {
                            "name": "Alicia Bargo",
                            "role": "CONTACT",
                            "phone": "212-342-4435",
                            "email": "ab5172@cumc.columbia.edu"
                        },
                        {
                            "name": "Maria Diaz, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Duke University",
                    "status": "RECRUITING",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27710",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Erin Severance",
                            "role": "CONTACT",
                            "phone": "919-668-6230",
                            "email": "erin.k.bell@duke.edu"
                        },
                        {
                            "name": "Annick Desjardins, MD, FRCPC",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                },
                {
                    "facility": "The Cleveland Clinic",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "David Peereboom, MD",
                            "role": "CONTACT",
                            "phone": "216-445-6068",
                            "email": "peerebd@ccf.org"
                        },
                        {
                            "name": "Rachel Hufsey, RN",
                            "role": "CONTACT",
                            "email": "hufseyr@ccf.org"
                        },
                        {
                            "name": "David Peereboom, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "Lifespan Cancer Institute/Rhode Island Hospital",
                    "status": "RECRUITING",
                    "city": "Providence",
                    "state": "Rhode Island",
                    "zip": "02903",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Nuno Rodrigues, RN",
                            "role": "CONTACT",
                            "phone": "401-444-3059",
                            "email": "908306@Lifespan.org"
                        },
                        {
                            "name": "Francesca Rothell, MS",
                            "role": "CONTACT",
                            "phone": "401.606.5488",
                            "email": "frothell@Lifespan.org"
                        },
                        {
                            "name": "Eric Wong, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.82399,
                        "lon": -71.41283
                    }
                },
                {
                    "facility": "UT MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Carlos Kamiya Matsuoka, MD",
                            "role": "CONTACT",
                            "phone": "713-408-3538",
                            "email": "CKamiya@mdanderson.org"
                        },
                        {
                            "name": "Evguenia Gachimova, RN",
                            "role": "CONTACT",
                            "phone": "832-266-3519",
                            "email": "Egachimova@mdanderson.org"
                        },
                        {
                            "name": "Carlos Kamiya Matsuoka, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "University of Utah, Huntsman Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84112",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Rachel Kingsford",
                            "role": "CONTACT",
                            "phone": "801-585-0115",
                            "email": "rachel.kingsford@hci.utah.edu"
                        },
                        {
                            "name": "Yuri Kida",
                            "role": "CONTACT",
                            "phone": "801-646-4397",
                            "email": "yuri.kida@hci.utah.edu"
                        },
                        {
                            "name": "Howard Colman, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000005909",
                    "term": "Glioblastoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001254",
                    "term": "Astrocytoma"
                },
                {
                    "id": "D000005910",
                    "term": "Glioma"
                },
                {
                    "id": "D000018302",
                    "term": "Neoplasms, Neuroepithelial"
                },
                {
                    "id": "D000017599",
                    "term": "Neuroectodermal Tumors"
                },
                {
                    "id": "D000009373",
                    "term": "Neoplasms, Germ Cell and Embryonal"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009380",
                    "term": "Neoplasms, Nerve Tissue"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9019",
                    "name": "Glioblastoma",
                    "asFound": "Glioblastoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4561",
                    "name": "Astrocytoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M9020",
                    "name": "Glioma",
                    "relevance": "LOW"
                },
                {
                    "id": "M20446",
                    "name": "Neoplasms, Neuroepithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M19845",
                    "name": "Neuroectodermal Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20388",
                    "name": "Neuroectodermal Tumors, Primitive",
                    "relevance": "LOW"
                },
                {
                    "id": "M12318",
                    "name": "Neoplasms, Germ Cell and Embryonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12325",
                    "name": "Neoplasms, Nerve Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "T2518",
                    "name": "Glioblastoma",
                    "asFound": "Glioblastoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2519",
                    "name": "Glioma",
                    "relevance": "LOW"
                },
                {
                    "id": "T4092",
                    "name": "Neuroepithelioma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000518",
                    "term": "Eflornithine"
                },
                {
                    "id": "D000077204",
                    "term": "Temozolomide"
                }
            ],
            "ancestors": [
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000014344",
                    "term": "Trypanocidal Agents"
                },
                {
                    "id": "D000000981",
                    "term": "Antiprotozoal Agents"
                },
                {
                    "id": "D000000977",
                    "term": "Antiparasitic Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000065108",
                    "term": "Ornithine Decarboxylase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1692",
                    "name": "Temozolomide",
                    "asFound": "Cervical",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3859",
                    "name": "Eflornithine",
                    "asFound": "Squamous cell carcinoma of the larynx",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4298",
                    "name": "Antiprotozoal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4294",
                    "name": "Antiparasitic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "T13",
                    "name": "Ornithine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                }
            ]
        }
    },
    "hasResults": false
}